The NAB1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the Raji human B lymphoblast cell line. This heterogeneous loss-of-function model enables investigation of NAB1, a transcriptional corepressor that regulates gene expression programs central to cell proliferation, differentiation, and apoptosis. The polyclonal format preserves biological diversity and is suited for population-based assays such as transcriptional profiling and functional cancer studies. It provides researchers with a versatile tool to study NAB1-dependent regulatory mechanisms without monoclonal isolation.
Raji is a well-characterized Burkitt lymphoma B-cell line, EBV-positive, derived from an African patient. These cells exhibit mature B-cell features including antibody production and antigen presentation, making them a standard model for immunological and oncological research. Their robust growth and relevance to B-cell biology provide an ideal background for CRISPR-mediated gene disruption studies. In particular, Raji cells are widely used to explore signaling pathways underlying B-cell malignancies and immune memory.
NAB1 acts as a transcriptional corepressor by directly binding to EGR transcription factors??EGR1, EGR2, and EGR3??and repressing their target genes. It operates within the MAPK/ERK signaling cascade, where EGR1 is rapidly induced downstream of RAF, MEK, and ERK. NAB1 also complexes with NAB2, SIN3A, and HDAC1 to mediate silencing. Key downstream targets repressed by NAB1 include TGF-??1, PDGF, and p53, linking mitogenic and stress signals to cellular outcomes. Disruption of NAB1 thus permits precise analysis of this corepressor function.
In Raji lymphoma cells, loss of NAB1 repression is predicted to alter EGR target gene expression, influencing proliferation, survival, and differentiation. This model is particularly relevant for studying B-cell receptor signaling and TGF-?? pathways implicated in Burkitt lymphoma. The polyclonal knockout population mimics tumor heterogeneity, enabling investigation of how NAB1 dysfunction impacts oncogenic networks and identifies potential therapeutic vulnerabilities.
Typical applications include quantitative gene expression analysis by RT-qPCR and RNA-seq, protein detection by Western blotting, EGR-mediated transcription assays via dual-luciferase reporter, and phenotypic profiling by flow cytometry. Functional assays such as MTT proliferation and Annexin V apoptosis measurements are supported. These cells are also suitable for CRISPR-based gene function screens and drug target identification efforts in B-cell malignancies. For additional technical information or custom inquiries, please contact Ascent Research.
